경구용 활성효소 억제제 복용 암환자의 잠재적 약물상호작용 연구
Potential Drug Interactions in Cancer Patients on Oral Kinase Inhibitors
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Among many new drugs that are under investigation with intent to treat cancer, oral kinase inhibitors are proven to be effective in numerous clinical trials and easy to administer. Due to these advantages the use of oral kinase inhibitors is increasing. Oral kinase inhibitors are metabolized by CYP450 which can result either increase of adverse effect or decrease of drug effect by drug interaction when used concurrently with other agents. In this research, the medication records of patients on oral kinase inhibitors from Oct. 2010 to Nov. 2011 were reviewed to investigate potential drug interactions. Methods: From Oct. 2010 to Nov. 2011, cancer patients in Inha University Hospital who took oral kinase inhibitors more than once were included. The patients' medication records were reviewed to list out concurrent medications that have interaction potential with oral kinase inhibitors, the frequency of concurrent use, and the severity of interaction result using Micromedex® and Lexicomp-online® as references. Results: As a result, 90 cases of drug with interaction potential were prescribed by Micromedex® and 179 cases by Lexicomp-online® data. In case of severity, 33.3% by Micromedex® and 26.3% by Lexicomp-online® were categorized as Major and 65.6% by Micromedex® and 72.6% by Lexicomp-online® as Moderate. The number of adverse events was 92 cases which 58.7% were on skin and 19.6% on Gastro-intestinal tract. Conclusions: Considerable number of drug with interaction potential was used though each oral kinase inhibitors showed differences in extent. Hence there exists the risk of drug interaction in patients taking oral kinase inhibitors with other drugs.
Abstract
Objectives: Among many new drugs that are under investigation with intent to treat cancer, oral kinase inhibitors are proven to be effective in numerous clinical trials and easy to administer. Due to these advantages the use of oral kinase inhibitors is increasing. Oral kinase inhibitors are metabolized by CYP450 which can result either increase of adverse effect or decrease of drug effect by drug interaction when used concurrently with other agents. In this research, the medication records of patients on oral kinase inhibitors from Oct. 2010 to Nov. 2011 were reviewed to investigate potential drug interactions. Methods: From Oct. 2010 to Nov. 2011, cancer patients in Inha University Hospital who took oral kinase inhibitors more than once were included. The patients' medication records were reviewed to list out concurrent medications that have interaction potential with oral kinase inhibitors, the frequency of concurrent use, and the severity of interaction result using Micromedex® and Lexicomp-online® as references. Results: As a result, 90 cases of drug with interaction potential were prescribed by Micromedex® and 179 cases by Lexicomp-online® data. In case of severity, 33.3% by Micromedex® and 26.3% by Lexicomp-online® were categorized as Major and 65.6% by Micromedex® and 72.6% by Lexicomp-online® as Moderate. The number of adverse events was 92 cases which 58.7% were on skin and 19.6% on Gastro-intestinal tract. Conclusions: Considerable number of drug with interaction potential was used though each oral kinase inhibitors showed differences in extent. Hence there exists the risk of drug interaction in patients taking oral kinase inhibitors with other drugs.
참고문헌 (27)
- Arora A, "Role of Tyrosine Kinase Inhibitors in Cancer Therpy", J Pharmachol Exp Ther, 315(3), pp.971~979 (2005)
- Steeghs N, "Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments", Ann Surg Oncol, 14(2), pp.942~953 (2007)
- Capizzi RL, "Combination Chemotherapy–theory and practice", Semin Oncol, 4(2), pp.227~253 (1977)
- Scripture CD, "Drug interactions in cancer therapy", Nat Rev Cancer, 6(7), pp.546~558 (2006)
- Van Erp NP, "Clinical pharmacokinetics of tyrosine kinase inhibitors", Cancer Treat Rev, 35(8), pp.692~706 (2009)
- 홍경자, "약물상호작용의 이해" (2003), 신일상사
- Hartmann JT, "Clinical pharmacokinetics of tyrosine kinase inhibitors", Curr Drug Metab, 10, pp.470~481 (2009)
- Tanaka C, "Effect of Rifampin and Ketoconazole on the pharmacokinetics of nilitinib in healthy participants", J Clin Pharmacol, 51(1), pp.75~83 (2011)
- van Leeuwen, "Potential drug interaction in cancer therapy : a prevalence study using an advanced screening method", Ann Oncol, 22, pp.2334~2341 (2011)
- Guastaldi RB, "Prevalence of potential drug-drug interactions in bone marrow transplant patients", Int J Clin Pharm, 33(6), pp.1002~1009 (2011)
- "Collaborating Center for Drug Statistics Methodology"[URL]
- "Thompson Reuters Micromedex®2.0" (2012)[URL]
- "Lexi-interact TM Online"[URL]
- Ogawa R, "Clinically significant drug interactions with antacid: an update", Drugs, 71, pp.1839~1864 (2011)
- Eley T, "Phase 1 study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects", J Clin Pharmacol, 49, pp.700~709 (2009)
- Sparano BA, "Effect of antacid on imatinib absorption", Cancer Chemother Pharmacol, 63, pp.525~528 (2009)
- "Tarceva prescribing information"[URL]
- "Iressa product information"[URL]
- Writht A, "Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools", Am J Health Syst Pharm, 69, pp.221~227 (2012)
- "ASHP 2009. Drug Interaction Alerts: The Battle against alert fatigue"[URL]
- "ASHP Guidelines on Medication-Use-Evaluation" (1996)[URL]
- Moura CS, "Evaluation of drugdrug interaction screening software combined with pharmacist intervention", Int J Clin Pharm (2012)[DOI]
- Hartmann JT, "Tyrosine Kinase Inhibitors–A Review on Pharmacology, Metabolism and Side Effects", Curr Drug Metab, 10, pp.470~481 (2009)
- "Gleevec product information"[URL]
- "Tykerb product information"[URL]
- "Nexavar product information"[URL]
- "Sutent prescribing information" (2012)[URL]